Autolus Therapeutics (US:AUTL) — Company Overview, News & Financial Data
Autolus Therapeutics develops next-generation T cell therapies for cancer treatment, aiming to improve clinical outcomes for patients.
About Autolus Therapeutics
Autolus Therapeutics (NASDAQ:AUTL) is a biopharmaceutical company focused on the development and commercialization of next-generation programmed T cell therapies for the treatment of cancer. The company's pioneering work in CAR T cell therapy, aimed at harnessing the power of patients' immune systems to combat cancer, positions it at the forefront of cell and gene therapy. Autolus Therapeutics is committed to advancing a diverse portfolio of treatment candidates, with a primary objective of delivering life-changing benefits to patients facing serious diseases. Through innovative research and strategic partnerships, the company aims to improve clinical outcomes and fundamentally alter the cancer treatment landscape.
Snapshot
Operations
Produtos e/ou serviços de Autolus Therapeutics
- Obe-cel (AUTO1): A CAR T-cell therapy aimed at treating adult acute lymphoblastic leukemia with a focus on reducing toxicity.
- AUTO1/22: A dual-targeting CAR T-cell therapy designed for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
- AUTO3: A dual-targeting CAR T-cell therapy for the treatment of pediatric acute lymphoblastic leukemia, emphasizing safety and efficacy.
- AUTO4: A T-cell receptor (TCR) therapy targeting TRBC1 for patients with T cell lymphomas, exploring a novel approach in cancer treatment.
- AUTO6: A CAR T-cell therapy focused on the treatment of solid tumors, aiming to expand the applicability of CAR T technology beyond hematological malignancies.
equipe executiva do Autolus Therapeutics
- Dr. Christian Martin Itin Ph.D.CEO & Director
- Mr. Alex DriggsSenior VP of Legal Affairs & General Counsel and Secretary
- Dr. Christopher WilliamsChief Business Officer
- Dr. Matthias Will M.D.Senior VP & Chief Development Officer
- Dr. Martin Pule M.D., MBBSFounder, Senior VP & Chief Scientific Officer
- Mr. Robert F. DolskiSenior VP & CFO
- Mr. Christopher VannSenior VP & COO
- Mr. Patrick McIlvennySenior VP of Finance, Chief Accounting Officer & Principal Accounting Officer
- Ms. Miranda NevilleChief Technology Officer
- Ms. Olivia ManserDirector of Investor Relations